Outset Medical Inc

Outset Medical Inc(OM)股票分析

$4.100

-0.314 (-7.66%)收盤時

Loading chart…
最高
4.375
開盤
4.210
成交量加權均價
4.12
成交量
163.02K
市值
214.13M
最低
3.890
成交金額
671.92K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.82

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

AI 分析 of Outset Medical Inc (OM)

持有

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

估值指標

Outset Medical Inc(OM)目前預期本益比為 0.00,5 年平均預期本益比為 -5.84。

預期本益比

高估
5 年均值 P/E
-5.84
目前P/E
0.00
高估
-1.00
低估
-10.68

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-4.71
目前EV/EBITDA
-0.82
高估
-0.51
低估
-8.92

預期股價營收比

合理
5 年均值 P/S
4.35
目前P/S
0.60
高估
9.32
低估
-0.63

Alphio AI 對 OM 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%OM

$19.05

情境價格

基

基準

基準 · 50%OM

$18.74

情境價格

悲

悲觀

悲觀 · 25%OM

$14.07

情境價格

持有 OM 的大戶

K

Konwave AG (Gold 2000)

+ 持有OM

+3.50%

3個月報酬率

事件時間軸

2026-05-07 (ET)

16:50:00

Company Reports Q1 Revenue of $27.86M, Below Expectations

16:50:00

Outset Reiterates 2026 Revenue Guidance of $125M to $130M

2026-02-11 (ET)

16:10:00

Outset Provides 2026 Revenue Guidance of $125M to $130M

16:10:00

Outset Medical Reports Q4 Revenue of $28.87M

2026-01-27 (ET)

09:10:00

Outset Medical Receives FDA 510(k) Clearance

資訊

OM 常見問題 —— 由 Alphio AI 解答

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易